Lactic acid/citric acid/potassium bitartrate, sold under the brand name Phexxi, is a non-hormonal combination medication used as a method of birth control. It contains lactic acid, citric acid, and potassium bitartrate. It is a gel inserted into the vagina.The most common adverse reactions include vulvovaginal burning sensation, vulvovaginal pruritus, vulvovaginal mycotic infection, urinary tract infection, vulvovaginal discomfort, bacterial vaginosis, vaginal discharge, genital discomfort, dysuria, and vulvovaginal pain. Medical uses
The combination is indicated for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception. History
The combination was approved for medical use in the United States in May 2020. References
External links
"Lactic acid". Drug Information Portal. U.S. National Library of Medicine. "Citric acid". Drug Information Portal. U.S. National Library of Medicine. "Potassium bitartrate". Drug Information Portal. U.S. National Library of Medicine.
Treatment
Treatment largely depends upon individual disease progression and the nature of presenting symptoms. Antimalarials, corticosteroids, and other drugs may be prescribed, if deemed appropriate by the treating physician. Prognosis
Most patients will maintain a diagnosis of undifferentiated connective tissue disease. However, about one third of UCTD patients will differentiate to a specific autoimmune disease, like rheumatoid arthritis or systemic sclerosis. About 12 percent of patients will go into remission.Severe vitamin D deficiency has been associated with the progression of UCTD into defined connective tissue diseases. The presence of the autoantibodies anti-dsDNA, anti-Sm, and anti-cardiolipin has been shown to correlate with the development of systemic lupus erythematosus, specifically. References


== External links ==